BioCentury | Feb 8, 2019
Finance

Earnings on deck

Earnings on deck At least 6 profitable biotechs and pharmas are slated to report earnings this week. (A) Premarket on U.S. exchange; during trading hours in Tel Aviv; (B) Premarket on U.S. exchange; during trading...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BioCentury | Oct 6, 2017
Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
BioCentury | Oct 6, 2017
Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
BC Extra | Sep 18, 2017
Company News

Management tracks: Kamada, Vertex, Addex, Achillion

Orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said Deputy CEO and CFO Gil Efron will leave at the end of the year. Chaime Orlev will become CFO, effective Jan. 1, 2018. Orlev was CFO...
BC Week In Review | Sep 1, 2017
Clinical News

FDA approves Kamada anti-rabies therapy Kedrab

Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said FDA approved Kedrab (human anti-rabies IgG therapy) for post-exposure prophylaxis of rabies infection when given immediately after contact with a suspected rabid animal. The anti-rabies IgG should be given...
BC Extra | Aug 25, 2017
Company News

FDA approves Kamada's anti-rabies therapy

Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said FDA approved Kedrab for post-exposure prophylaxis of rabies infection when given immediately after contact with a suspected rabid animal. The anti-rabies IgG should be given concurrently with a full...
BC Week In Review | Aug 4, 2017
Financial News

Follow-on Roundup: Actinium, Kamada, Tetraphase

Immunotherapy play Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) and infectious disease company Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) each priced follow-on offerings, raising more than $96 million combined. Actinium raised $16.1...
BC Extra | Jul 28, 2017
Financial News

Follow-on roundup: Actinium, Kamada, Tetraphase

Immunotherapy play Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) and infectious disease company Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) each priced follow-on offerings, raising more than $96 million combined. Actinium raised $16.1...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
Items per page:
1 - 10 of 105
BioCentury | Feb 8, 2019
Finance

Earnings on deck

Earnings on deck At least 6 profitable biotechs and pharmas are slated to report earnings this week. (A) Premarket on U.S. exchange; during trading hours in Tel Aviv; (B) Premarket on U.S. exchange; during trading...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BioCentury | Oct 6, 2017
Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
BioCentury | Oct 6, 2017
Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
BC Extra | Sep 18, 2017
Company News

Management tracks: Kamada, Vertex, Addex, Achillion

Orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said Deputy CEO and CFO Gil Efron will leave at the end of the year. Chaime Orlev will become CFO, effective Jan. 1, 2018. Orlev was CFO...
BC Week In Review | Sep 1, 2017
Clinical News

FDA approves Kamada anti-rabies therapy Kedrab

Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said FDA approved Kedrab (human anti-rabies IgG therapy) for post-exposure prophylaxis of rabies infection when given immediately after contact with a suspected rabid animal. The anti-rabies IgG should be given...
BC Extra | Aug 25, 2017
Company News

FDA approves Kamada's anti-rabies therapy

Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said FDA approved Kedrab for post-exposure prophylaxis of rabies infection when given immediately after contact with a suspected rabid animal. The anti-rabies IgG should be given concurrently with a full...
BC Week In Review | Aug 4, 2017
Financial News

Follow-on Roundup: Actinium, Kamada, Tetraphase

Immunotherapy play Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) and infectious disease company Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) each priced follow-on offerings, raising more than $96 million combined. Actinium raised $16.1...
BC Extra | Jul 28, 2017
Financial News

Follow-on roundup: Actinium, Kamada, Tetraphase

Immunotherapy play Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) and infectious disease company Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) each priced follow-on offerings, raising more than $96 million combined. Actinium raised $16.1...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
Items per page:
1 - 10 of 105